Plasma-Lyte 148® versUs Saline Study
NCT02721654
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
5037
Enrollment
OTHER
Sponsor class
Conditions
Hypovolemia
Interventions
DRUG:
Plasma-Lyte 148®
DRUG:
0.9% sodium chloride
Sponsor
The George Institute
Collaborators
[object Object]
[object Object]